Cardio/Renal--FINAL Flashcards
FDA-Approved cholesterol Drugs for Children
Statins (Atorvastatin, Pravastatin, etc.), Bile Acid Sequestrants, Ezetimibe.
Mechanism of Action - Statins
Inhibit HMG-CoA reductase → Decrease LDL, increase HDL.
Mechanism of Action - Niacin
Reduces hepatic VLDL synthesis, increases HDL.
Mechanism of Action - Bile Acid Sequestrants
Bind bile acids in intestine, increasing LDL clearance.
Mechanism of Action - Ezetimibe
Inhibits cholesterol absorption in small intestine.
Mechanism of Action - Fibrates
Activate PPAR-α to increase lipolysis of triglycerides.
Fenofibrate
Mechanism of Action - Omega-3 Fatty Acids
Reduce hepatic triglyceride production.
First-Line Therapy for Dyslipidemia
Statins (unless contraindicated).
Contraindications of Statins
Liver disease, pregnancy.
Contraindications of Niacin
Peptic ulcers, gout.
Contraindications of Fibrates
Severe kidney/liver disease.
Statin Potency
High: Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg; Moderate: Simvastatin 20-40 mg; Low: Pravastatin 10-20 mg.
Statin Drug Interactions
Gemfibrozil + Statins (myopathy risk); Cyclosporine, Erythromycin (increased toxicity).
Side note: shouldn’t really be taken with PPIs either.
PCSK9 Inhibitors
Name 2
Alirocumab (Praluent), Evolocumab (Repatha)→ Increase LDL clearance, used in familial hypercholesterolemia.
Unfractionated Heparin (UFH) MOA
Enhances antithrombin III → Inhibits thrombin & factor Xa.
UFH Monitoring
aPTT (target 1.5–2.5× normal).
UFH Antidote
Protamine sulfate.
Low-Molecular-Weight Heparins (LMWH)
Enoxaparin, Dalteparin → More predictable, no aPTT monitoring.
Fondaparinux (Arixtra)
Factor Xa inhibitor, no risk of HIT.
Warfarin MOA
Inhibits vitamin K-dependent clotting factors (II, VII, IX, X).
Warfarin Monitoring
INR (target 2.0–3.0; mechanical valves 2.5–3.5).
Warfarin Antidote
Vitamin K, Fresh Frozen Plasma (FFP), PCC (Prothrombin Complex Concentrate containing clotting factors II, VII, IX, and X that are all inhibited by warfarin
Direct Oral Anticoagulants (DOACs)
Dabigatran (Pradaxa, Factor IIa inhibitor); Rivaroxaban, Apixaban (Factor Xa inhibitors).
Reversal Agents for DOACs
Idarucizumab (Pradaxa); Andexanet alfa (Xarelto/Eliquis).